MRNA Stock: Price, Earnings History and SEC Filings
Moderna, Inc. (MRNA) last traded at $221.72, down 0.47% on the latest session and up 15.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.97 against an analyst estimate of $-1.97, a beat of 0.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MRNA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 31, 2026 | $-1.97 | $-1.97 | +0.00% |
| Mar 2026 | May 1, 2026 | $-1.18 | $-3.02 | +60.93% |
| Dec 2025 | Feb 13, 2026 | $-2.11 | $-2.60 | +18.85% |
| Sep 2025 | Nov 6, 2025 | $-0.51 | $-2.15 | +76.28% |
MRNA beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How MRNA reacts to earnings
Across its last 8 earnings releases, MRNA moved 4.0% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-31 | Before open | -5.35% |
| 2026-05-01 | Before open | -1.24% |
| 2026-02-13 | Before open | +5.29% |
| 2026-01-12 | Before open | -1.34% |
| 2025-11-06 | Before open | +3.27% |
| 2025-08-01 | Before open | -6.61% |
| 2025-05-01 | Before open | -5.29% |
| 2025-02-14 | Before open | +3.35% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
MRNA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1.9B | -$2.8B | -$2.1B | -145.2% | $-7.26 |
| 2024 | $3.2B | -$3.6B | -$4.1B | -110.0% | $-9.28 |
| 2023 | $6.8B | -$4.7B | -$3.8B | -68.8% | $-12.33 |
| 2022 | $19.3B | $8.4B | $4.6B | 43.4% | $20.12 |
| 2021 | $18.5B | $12.2B | $13.3B | 66.1% | $28.29 |
| 2019 | $60M | -$514M | -$491M | -853.7% | $-1.55 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for MRNA
- 8-K · Sep 30, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 1, 2026Material agreement, New financial obligation, Unregistered share sale
- 10-Q · Jul 31, 2026
- 8-K · Jul 31, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 8, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · May 11, 2026Bylaw change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 1, 2026
- 8-K · May 1, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Mar 16, 2026
- 8-K · Mar 5, 2026Material agreement
Insider filing activity
MRNA insiders filed 13 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
MRNA news
- Jobs, Midterm Elections, Apple, Palantir, McDonald’s, Moderna, and More to Watch This WeekNov 1, 2026 · finance.yahoo.com
- Merck stock rises as its cancer strategy gets personalNov 1, 2026 · thestreet.com
- What To Expect In Markets This Week: AAPL, PLTR, AMD, SMCI, SHOP, Earnings, Jobs Report And MoreNov 1, 2026 · stocktwits.com
- How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine DataOct 31, 2026 · finance.yahoo.com
- This week in charts: ESMO’s winners and losersOct 30, 2026 · biopharmadive.com
- Prediction markets herald insider trading risks for private biotechsOct 30, 2026 · pharmaceutical-technology.com
- Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to DeclineOct 30, 2026 · finance.yahoo.com
- Merck & Co., Inc. Q3 Earnings Call HighlightsOct 30, 2026 · marketbeat.com
About Moderna, Inc.
Moderna, Inc. (MRNA) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.